81 results about "Arachnoid Membrane" patented technology

Methods, devices and systems for draining fluid from the eye and / or for reducing intraocular pressure. A passageway (e.g., an opening, puncture or incision) is formed in the lamina cribosa or elsewhere to facilitate flow of fluid from the posterior chamber of the eye to either a) a subdural location within the optic nerve or b) a location within the subarachnoid space adjacent to the optic nerve. Fluid from the posterior chamber then drains into the optic nerve or directly into the subarachnoid space, where it becomes mixed with cerebrospinal fluid. In some cases, a tubular member (e.g., a shunt or stent) may be implanted in the passageway. A particular shunt device and shunt-introducer system is provided for such purpose. A vitrectomy or vitreous liquefaction procedure may be performed to remove some or all of the vitreous body, thereby facilitating creation of the passageway and / or placement of the tubular member as well as establishing a route for subsequent drainage of aqueous humor from the anterior chamber, though the posterior chamber and outwardly though the passageway where it becomes mixed with cerebrospinal fluid.

An implantable system for the treatment of hydrocephalus includes a plurality of microneedles in a fixed array relative to each other adapted to extend from the subarachnoid space containing CSF surrounding the brain, through dura mater forming the wall of the superior sagital sinus. A microvalve is associated with a proximal end of each of the microneedles and is adapted to permit the flow of cerebrospinal fluid (CSF) from the subarachnoid space through the wall of the superior sagital sinus and deposited in the venous return of the brain. The method of treating hydrocephalus with the system of this invention also constitutes a part of the invention.

This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, and biological agents or compounds with added supportive therapies administered through OM, SAS, IVB, IV, and IA routes. An embodiment provides devices for intranasal delivery of therapeutic agents to olfactory mucosal area. Another embodiment uses the technology to deliver the therapeutic, pharmaceutical, biochemical, and biological agents or compounds to the subarachnoid space and ventricular system by using continuous catheters and Ommaya reservoir at the same time. The present method incorporates breaking the blood brain barrier to allow the entry of the anti rabies therapeutic agents into the neuropile. Additionally, an embodiment incorporates cooling of the brain and inducing hibernation to preserve the brain from damage due to rabies.

A composition and method for treating and preventing injury to central nervous system tissue are provided. The composition is comprised of agents that can increase colloidal osmotic pressure and osmolality. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition into subarachnoid spaces.

The present invention relates to a fashudil hydrochloride oral preparation for curing ischemic cerebrovascular disease due to cerebrovascular spasm after subarachnoid hemorrhage. It can be made into tablet, capsule and granule preparation.

A catheter system and method for selectively cooling or freezing target neuronal tissue to induce lesions along the neuroaxis and produce cryoanalgesia by impairing nerve conduction of the targeted neuronal tissue. The system includes a catheter that has cryogenic capability for variable cooling or freezing of neuronal tissue. The catheter also includes temperature sensing and electrodiagnostic capabilities. A pressurized fluid source is included for inflating a portion of the catheter body. The system includes electrodiagnostic equipment for stimulating and monitoring sensory evoked potentials in the patient. The method involves placement of the catheter tip in the subarachnoid space of the spinal canal and location of the tip on the neuronal target using imaging and electrodiagnostic techniques.

Apparatus is provided that includes a parenchymal electrode, configured to be implanted in brain parenchyma of a subject identified as at risk of or suffering from a synucleinopathy; and a cerebrospinal fluid (CSF) electrode, configured to be implanted in a CSF-filled space of a brain of the subject, the CSF-filled space selected from the group consisting of: a ventricular system and a subarachnoid space. Control circuitry is configured to drive the parenchymal and the CSF electrodes to clear alpha-synuclein (aSyn) from the brain parenchyma into the CSF-filled space of the brain. Other embodiments are also described.

A subarachnoid pharmacodialysis apparatus insertable under the scalp, in and under the cranium, with a relatively short and simple neurosurgical procedure, to be kept there safely implanted for a year or longer for the purpose of regulating the neurochemistry of one or more diseased cerebral cortical areas and thus to achieve therapeutic effects via both localized delivery of medication and drainage of local neurotoxic molecules across the subdural meninges and compartments in a feedback-controlled fashion, with or without the additional capability of performing localized neurochemistry regulation in subcortical areas. This apparatus is also used for neurochemical profiling of the diseased brain area or areas by analyzing the removed endogenous molecules and adjusting the composition of the delivered medication based on the patient's specific, abnormal neurochemistry within the treated area or areas.

The invention discloses a craniocerebral operation training simulation model comprising a simulation skull bottom and a simulation skull top cover. The simulation skull bottom and the simulation skulltop cover are detachably connected to form a simulation skull cavity. A simulated ventricle, a simulated brain tissue, a simulated subarachnoid space, a simulated dura mater and a simulated cerebralhematoma are arranged on the inner side of the simulated skull cavity; and a simulation blood vessel is arranged at the bottom of the inner side of the bottom of the simulation skull. According to theinvention, various structures, including skull, dura mater, subarachnoid space, blood vessels, hematoma, ventricle and the like, of the brain of a cerebral hemorrhage patient can be simulated; so that the simulated surgery of cerebral hemorrhage is close to actual operation in the aspects of image interpretation, operation path design, hematoma positioning, skull drilling, bone window forming, dura mater incision, hematoma puncture, hematoma flushing and drainage, channel implantation, microscope or endoscope hematoma removal and the like as much as possible, various simulated operation operations are performed on the model, and various operation skills of cerebral hemorrhage treatment of clinicians are trained.

The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefitting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.

The invention discloses an application of rapamycin of formula (I) in the preparation of a pharmaceutical composition for treating early brain injury after subarachnoid hemorrhage. The present invention proves through experiments that RAP can enhance autophagy, reduce brain edema, reduce the permeability of the blood-brain barrier and alleviate clinical symptoms, thereby alleviating EBI after SAH, and then protecting the brain tissue, providing a basis for the treatment of EBI after SAH A new approach to treatment.

Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide.

The invention which belongs to the technical field of medicines concretely relates to a Fasudil hydrochloride hydrate and a preparation method thereof. Fasudil hydrochloride prepared in the invention which has three and a half crystal waters has the advantages of high purity, good stability, unapparent weight gain of moisture absorption in a high humidity condition and good formability. The invention also relates to an application of the hydrate in preparing drugs for improving and preventing ischemic cerebrovascular diseases caused by a plurality of reasons, such as cerebral infarction, vertebrobasilar artery insufficiency, delayed cerebrovascular disease caused by subarachnoid hemorrhage, cerebral vasospasm caused by brain surgery and interventional therapies, and transient ischemic attack.

Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.

The invention belongs to the technical field of medical treatment and discloses an analgesia method and device suitable for a patient with advanced cancer pain. The analgesia method and device suitable for the patient with advanced cancer pain are mainly used for intra-vertebral-canal dosage analgesia treatment for the patient with advanced cancer pain. The analgesia device suitable for the patient with advanced cancer pain at least comprises a detachable extracorporeal conduit fixator, a handle type subcutaneous tunneler, a silica gel conduit, an epidural puncture needle and other accessories, and is characterized in that the silica gel conduit is implanted under the skin, one end of the conduit is implanted to an epidural space or a cavum subarachnoidale, the other end of the conduit penetrates out of the skin of the belly, is connected with the detachable extracorporeal conduit fixator and is fixed to the skin of the belly through the detachable extracorporeal conduit fixator, and therefore a firm intra-vertebral-canal dosage passage is provided. The detachable extracorporeal conduit fixator is further connected with a portable extracorporeal electronic dosage pump. In this way, analgesia medicine is conveyed to the vertebral canal through the detachable extracorporeal conduit fixator and the silica gel conduit, and an efficient analgesia effect is achieved.

A safe combined puncture epidural anesthesia puncture needle is mainly composed of an epidural puncture needle, an epidural puncture needle core, a lumbar puncture needle and a lumbar puncture needle core. The arc-shaped crook of the epidural puncture needle is provided with a lumbar puncture dorsal pore. The epidural puncture needle core is composed of a safety protection device at the front part, a negative pressure conduction device in the middle, a negative pressure display device at the rear part, an elastic forward device at the tail part and a needle core base, and an epidural puncture needle core is connected with an lumbar puncture needle rear base in a detachable fixing manner. Apart from achieving the purpose of identifying the epidural space doubly, the puncture needle can avoid the needle point of the epidural puncture needle and the epidural conduit entering the subarachnoid space by the needle hole of the lumbar puncture needle, the lumbar puncture needle is prevented from being broken, and the lumbar puncture needle is conveniently fixed in the epidural puncture needle.

The invention discloses application of sorafenib shown in a formula (I) to the preparation of a medicinal composition for treating cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). Animal experiments prove that BAY 43-9006 has the effect of obviously inhibiting the CVS after the SAH, and can be used for improving the CVS after the SAH.

The invention provides a dynamic test system based on a high-simulation physical head model and a protection evaluation method. The high-simulation physical head model is established completely basedon a head anatomical structure and mechanical properties of biological tissues of each part of the head anatomical structure, so that the occurrence process of two common injuries, namely brain tissuecontusion and subarachnoid hemorrhage, can be truly represented; a skull and brain tissue relative tangential displacement measurement system, an intracranial pressure dynamic test system, a skull strain dynamic test system, a skull acceleration dynamic test system and a head overall acceleration test system are established, and six biomechanical injury indexes for evaluating the degree of craniocerebral injury can be obtained; the damage state corresponding to the head model without wearing the protective equipment is taken as a reference; based on the six mechanical damage indexes and the severity of brain tissue contusion and rupture and subarachnoid hemorrhage, mechanical damage evaluation and physiological damage evaluation are conducted on the biological protection efficiency of thehead protection equipment, and therefore comprehensive evaluation of the protection equipment is achieved.

The invention provides an application of extracellular vesicles derived from mesenchymal stem cells in treatment of subarachnoid hemorrhage, which belongs to the technical field of molecular biology.The MSCs extracellular vesicles (MSCs-EVs) have the effects of relieving SAH complications, and improving prognosis and the like. Specifically, the MSCs-EVs can effectively improve the neuroinflammation reaction after subarachnoid hemorrhage (SAH), promote the phenotypic transformation of microglial cells to M2, and relieve the symptoms of neurological impairment, cerebral water content increase and the like caused by subarachnoid hemorrhage.

The invention provides a biomarker of subarachnoid hemorrhage indicating poor prognosis. The poor prognosis is delayed cerebral infarction, and the marker consists of the following miRNAs: miR-4463, miR-4532 and miR-1290, and may also comprises miR-4793. The invention also provides a method for diagnosing subarachnoid hemorrhage or prognosis thereof by using the biomarker. The invention also provides a kit and a chip containing the biomarker for diagnosing subarachnoid hemorrhage or prognosis thereof, and a preparation method thereof.

The present disclosure discusses a devices, systems and methods for transvascular, transvenous and / or transdural access, to the brain parenchyma, subarachnoid or subdural spaces. In some embodiments, the disclosed systems and methods may be used for local drug delivery, tissue biopsy, nanofluidic or microelectronic device / component delivery / insertion / implantation, in situ imaging, ablation of abnormal brain tissue and the like. Embodiments of the present disclosure include an access catheter system for extravascular procedures in the brain having an elongate, flexible tubular body, with at least one lumen extending axially there through between a proximal end, and a distal end. The access catheter system may include a side exit port and a distal end port. Further, the access catheter system may include a selective deflector positioned within the lumen configured to deflect a procedure catheter and permit a guide catheter.

The invention provides the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, and belongs to the technical field of biomedicine and molecular biology. According to the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, the potential therapeutic effects of mesenchymal stem cell exosomes in SAH are explored, particularly in the effect on cognitive function. It is proved that the mesenchymal stem cell exosomes can reduce early brain damage after SAH and improve the cognitive function. In the mechanism, it is demonstrated by the exosomesrich in miR-21 play an important role in mediating effect on inhibiting neuronal apoptosis. According to the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, it is actually proved that miR-21 in the mesenchymal stem cell exosomes reduces brain damage after SAH by inhibiting the neuronal apoptosis, the neural behavior is improved through a PTEN / Akt pathway, potentialnovel restorative treatment methods and strategies are provided for SAH patients with the risk of cognitive deficits, and thus the good practical application value is obtained.

The invention discloses a lumbar puncture needle capable of achieving puncture depth feedback and real-time cerebrospinal fluid pressure monitoring. The lumbar puncture needle comprises a measuring system and a puncture needle body. According to the measuring system, a method for detecting cerebrospinal fluid based on impedance and liquid pressure is designed; and the puncture needle main body comprises a puncture needle and a needle body, the puncture needle comprises an outer needle and an inner needle, an insulating coating is arranged in the outer needle, and the outer needle and the inner needle form a closed circuit with the measuring system through an electric lead. The lumbar puncture needle has the advantages that an alarm prompt can be given out when the puncture needle head makes contact with the lumbar vertebra subarachnoid space cerebrospinal fluid, the pressure of the cerebrospinal fluid can be monitored in real time in the cerebrospinal fluid reserving process, and the success rate and safety of the lumbar puncture operation can be improved.

The invention discloses an artificial cerebral dura mater for tightly mending intraoperative dural injury; the inner surface of the artificial cerebral dura mater is in contact with cerebral tissues, is smooth and is not in adhesion with arachnoid and cerebral tissues; the outer surface of the artificial cerebral dura mater is provided with a plurality of loops (1) for surgical sewing. It is very convenient to perform sewing during surgery, sewing is easy, post-sewing watertightness is good, the artificial cerebral dura mater is simple to operate and is smooth after being fixed, and the watertightness problem of existing artificial cerebral dura mater in use is solved.

The invention relates to quick, safe and accurate united puncture needle. The quick, safe and accurate united puncture needle comprises a spinal epidural puncture needle and an anesthetic needle. By arranging an arc-shaped groove which is axially parallel to a needle stem is formed in the other side, which is opposite to a first opening, of the needle stem of a puncture needle body and designing the arc-shaped groove in a structure of which the cross section is a major arc, the anesthetic needle can be wrapped by the arc-shaped groove which is of the major arc structure when the anesthetic needle slides in the arc-shaped groove, the anesthetic needle cannot deviate from the arc-shaped groove under muscle resistance, and the anesthetic needle can quickly, safely and accurately enter a subarachnoid space; since a wound generated on an arachnoid by the anesthetic needle deviates from the position where the first opening is located, when an epidural anesthetic catheter is inserted in an inner cavity of the puncture needle body, the epidural anesthetic catheter cannot be inserted in the subarachnoid space from the wound by mistake, the safety and the accuracy of anaesthesia are effectively increased, and a medical accident is prevented from occuring.

Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.